Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 345

Sort by

Sort Order Select

Journal Articles

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Blood (2024) 144 (23): 2389–2401.

https://doi.org/10.1182/blood.2024024582

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Yash Shah, Mark Fiala, Keith Stockerl-Goldstein, Mark A. Schroeder, Ravi Vij, Zachary D. Crees, Michael Slade

Blood (2024) 144 (Supplement 1): 3792.1.

https://doi.org/10.1182/blood-2024-209293

Published: 2024

Journal Articles

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2024) 144 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2024-200829

Published: 2024

Journal Articles

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Blood (2024) 144 (Supplement 1): 3357.

https://doi.org/10.1182/blood-2024-199797

Published: 2024

Journal Articles

Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Anthony Colombo, Esther Lam, Ben Falk, Anton Luis Villamejor, Amie Hwang, Jose Aparicio, Jia Yin Wan, Chun R. Chao, Mallory Bernstein, Ravi Vij, Mark Fiala, Pei Lin, Robert Z. Orlowski, Imran Siddiqi, David Conti, Akil Merchant, Wendy Cozen

Blood (2024) 144 (Supplement 1): 3327.

https://doi.org/10.1182/blood-2024-208818

Published: 2024

Journal Articles

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 2393.

https://doi.org/10.1182/blood-2024-203892

Published: 2024

Journal Articles

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Blood (2024) 144 (Supplement 1): 224.

https://doi.org/10.1182/blood-2024-201694

Published: 2024

Journal Articles

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Alexa Loncharich, Mark Fiala, Julie Fortier, Keith Stockerl-Goldstein, Ravi Vij, Mark A. Schroeder, Mark Zaydman, Michael Slade, Mariya Liyasova

Blood (2024) 144 (Supplement 1): 1921.

https://doi.org/10.1182/blood-2024-211395

Published: 2024

Journal Articles

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Blood (2024) 144 (Supplement 1): 1972.

https://doi.org/10.1182/blood-2024-210377

Published: 2024

Journal Articles

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Akhil Kesaraju, Alexa Loncharich, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Ravi Vij, Michael Slade

Blood (2024) 144 (Supplement 1): 6936.

https://doi.org/10.1182/blood-2024-208241

Published: 2024

Journal Articles

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Blood (2024) 144 (Supplement 1): 4654.

https://doi.org/10.1182/blood-2024-208308

Published: 2024

Journal Articles

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Michael Slade, Ravi Vij, Keith Stockerl-Goldstein, Mark A. Schroeder, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Mark Fiala

Blood (2024) 144 (Supplement 1): 3653.

https://doi.org/10.1182/blood-2024-203469

Published: 2024

Journal Articles

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Blood (2024) 144 (Supplement 1): 3792.5.

https://doi.org/10.1182/blood-2024-210957

Published: 2024

Journal Articles

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Blood (2023) 142 (Supplement 1): 4698.

https://doi.org/10.1182/blood-2023-181235

Published: 2023

Journal Articles

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

Ravi Vij, Suvina Amin, Jin Gu, Thomas S. Marshall, Susan Fish, Sujith Dhanasiri, Gabriela Hernandez, David Cella, Hartmut Goldschmidt, Karthik Ramasamy

Blood (2023) 142 (Supplement 1): 3786.

https://doi.org/10.1182/blood-2023-178500

Published: 2023

Journal Articles

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

Joshua Richter, Jeffrey A. Zonder, Nitya Nathwani, Giada Bianchi, Craig C. Hofmeister, Ravi Vij, Matthew Pianko, Gurbakhash Kaur, Malin Hultcrantz, Katie Wozniak, Mercedes Martillo, Hearn Jay Cho, Shaji Kunnathu Kumar

Blood (2023) 142 (Supplement 1): 3387.

https://doi.org/10.1182/blood-2023-184949

Published: 2023

Journal Articles

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 648.

https://doi.org/10.1182/blood-2023-189940

Published: 2023

Journal Articles

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Meaghan Ryan, Zachary David Crees, Michael Slade, Mark A. Schroeder, Ravi Vij, Geoffrey L Uy, Keith Stockerl-Goldstein

Blood (2023) 142 (Supplement 1): 2217.

https://doi.org/10.1182/blood-2023-179604

Published: 2023

Journal Articles

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Blood (2023) 142 (Supplement 1): 2101.

https://doi.org/10.1182/blood-2023-173970

Published: 2023

Journal Articles

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Michael Slade, Abir Khaled, Mark Fiala, Zac McDonald, Mariya Liyasova, Julie Fortier, Mark Zaydman, Sarah Kelley, Zachary David Crees, Mark A. Schroeder, Keith Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2023) 142 (Supplement 1): 3354.

https://doi.org/10.1182/blood-2023-172440

Published: 2023

NARROW

Ide-cel vs standard regimens in triple-class–exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses

Impact of Absolute Lymphocyte Counts (ALC) on Outcomes Following Bispecific Antibody Therapy in Patients with Relapsed/Refractory Multiple Myeloma Patients: A Single Center Real-World Experience

Idecabtagene Vicleucel (Ide-cel) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Front-Line Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Clinical Outcomes in Black Patients with Relapsed/Refractory Multiple Myeloma Following Talquetamab Treatment: Analyses from the Phase 1/2 Monumental-1 Study

Characterization of the Tumor Microenvironment of Diagnostic Bone Marrow Core Biopsies from African American Multiple Myeloma Patients Using Imaging Mass Cytometry

Feasibility and Implementation of the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Clearance of Leukemia Associated Mutations (LAMs) after Induction Therapy Is Associated with Favorable Outcomes in Intermediate Risk Acute Myeloid Leukemia: Interim Results of a Multicenter, Prospective Phase II Trial

Evaluating Diagnostic Performance of Light Chain Dimerization By Mass Spectrometry to Distinguish between AL Amyloidosis and Monoclonal Gammopathy of Undetermined Significance

Initial Results from the ASH Research Collaborative's COVID-19 Outcomes in Myeloma and the Impact of Vaccines (COSMIC): A Decentralized, Real-World Evidence Study for Patients with Multiple Myeloma to Monitor Outcomes Related to COVID-19 Vaccines and Infections

Real-World Experience with Elotuzumab, Pomalidomide, and Dexamethasone As Second or Third-Line Therapy in Relapsed and Refractory Multiple Myeloma

Single-Cell Analysis Reveals Depletion of Antigen-Presenting Cell (APC) and IFN-Stimulated CD4 T Cell Populations in High-Risk Newly Diagnosed Multiple Myeloma Patients

Convenience Versus Continuity: A Natural History Study of a Newly Opened Plasma Cell Disorders Clinic in an Underserved Community and Desire for Transfer of Care Among Previously Diagnosed Patients

Development of the ASH Research Collaborative Multiple Myeloma Program: A Multicenter, Real-World Evidence Generation Network

Outcomes of Patients with Extramedullary Disease in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from the LocoMMotion + MoMMent Studies

Treatment Patterns and Outcomes for Patients with Newly Diagnosed Multiple Myeloma Post-Stem Cell Transplantation Who Received Lenalidomide As First Line Maintenance Therapy (PREAMBLE)

Selinexor, Ixazomib, Pomalidomide and Dexamethasone in Functionally High-Risk Multiple Myeloma: Results from the Myeloma Developing Regimens Using Genomics (MyDRUG) Sub-Protocol Y3

In-Depth Characterization of the High Risk-Associated Tumor Immune Landscape in Multiple Myeloma

Patient Recorded Outcomes from a Randomized, Controlled Phase 2 Trial of E-Selectin Inhibition with Uproleselan Vs Placebo to Reduce GI Toxicity during Melphalan-Conditioned Autologous Hematopoietic Cell Transplantation for Multiple Myeloma

Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up

Measurable Residual Disease Status By Clonotypic Mass Spectrometry with Easym Assay Predicts Outcomes Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only